Pancreatic Cancer Research

ResearcherWest China Hospital of Sichuan UniversityNo recent work listed

Fei Xie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3674-8216; OpenAlex author ID A5100785688. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 1 paper

Papers 4

  1. Long noncoding RNA LINC01559 promotes pancreatic cancer progression by acting as a competing endogenous RNA of miR-1343-3p to upregulate RAF1 expression. Co-author DOI 10.18632/aging.103487↗
  2. MiR-345-5p functions as a tumor suppressor in pancreatic cancer by directly targeting CCL8. First author DOI 10.1016/j.biopha.2018.12.121↗
  3. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS. Co-author DOI 10.1016/j.biopha.2019.109424↗
  4. Expression of miRNA-143 in Pancreatic Cancer and Its Clinical Significance. Co-author DOI 10.1089/cbr.2018.2500↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tinggang Mou · 3 shared papers, 2018–2020 · strength 0.31
  2. Qin Yang · 2 shared papers, 2019–2020 · strength 0.23
  3. Hao Hua · 2 shared papers, 2019–2020 · strength 0.23
  4. Liang Lai · 2 shared papers, 2018–2019 · strength 0.19
  5. Wei Jun Peng · 1 shared paper, 2019 · strength 0.12
  6. Tianfu Wen · 1 shared paper, 2019 · strength 0.12
  7. Jie Wang · 1 shared paper, 2020 · strength 0.12
  8. Xiao Chen · 1 shared paper, 2020 · strength 0.12
  9. Jie Wang · 1 shared paper, 2019 · strength 0.11
  10. Bo Xu · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.